WG2 - Integration of early phase studies and low environmental impact actions

The recent COVID19 pandemic infection has undisclosed long-standing issues in the translation of drugs from animals to humans or vice-versa. Nearly 75% of emerging human infections worldwide originated from animals; existing drugs for human and animal (H&A) vector-borne diseases (VBD) are scarce, with limited efficacy, toxicity, and finite resources. Emerging environmental problems in pharmaceutical use/manufacturing increase attention in the field. The two drug pipelines are developed ...

The workshop “Novel leads and drugs and their mechanism of action in the field of vector borne parasitic disease” is jointly organized by WG1 “Compound libraries coordination and integration of compound design” and WG2 “Integration of early phase studies and low environmental impact actions” of the COST Action CA21111 OneHealthDrugs. The focus of the workshop is to bring together experts to report and discuss common definitions of novel leads and drugs and their mechanisms of action in view also ...